Comparison
Piracetam vs Fasoracetam
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
Fasoracetam
Atypical racetam under investigation for adolescent ADHD. Modulates GABA-B, mGluR, and cholinergic systems.
| Field | Piracetam | Fasoracetam |
|---|---|---|
| Category | racetam | racetam |
| Dose range | 1200–4800mg | 10–30mg |
| Half-life | 5h | 5h |
| Onset | 45min | 30min |
| Evidence | EVIDENCEA | EVIDENCEC |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USUnscheduled | USUnscheduled |
| PubMed refs | 1200 | 20 |
The comparison in plain English
Auto-generated from dataPiracetam and Fasoracetam are both in the racetam category respectively. Piracetam The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. Fasoracetam Atypical racetam under investigation for adolescent ADHD.
Bottom line
Piracetam (evidence A, safety 5/5) has a weaker evidence base than Fasoracetam (evidence C, safety 4/5). Piracetam has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Piracetam if
Piracetam is the better fit when your goal aligns with its mechanism (Modulates AMPA and NMDA glutamate receptors and enhances acetylcholine signaling via muscarinic receptor allosteric modulation) and the dose range (1200–4800mg) suits your protocol. Half-life is 5h.
Choose Fasoracetam if
Fasoracetam is the better fit when your goal aligns with its mechanism (Upregulates GABA-B receptors and modulates metabotropic glutamate receptor groups II and III) and the dose range (10–30mg) suits your protocol. Half-life is 5h.